Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs ResMed Inc. — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $1.83, while ResMed Inc. trades at $226.31 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none, and ResMed Inc. is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| MSTU | RMD | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $76.30 | $293.73 |
52-Week Low | $1.46 | $182.82 |
Market Cap | — | $32.61B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU, a leveraged ETF tracking MicroStrategy (MSTR), trades at $1.815, down 3.97% on the day, reflecting severe long-term erosion. The technical outlook is bearish with moving averages signaling strong selling pressure, while oscillators remain neutral. Recent news highlights catastrophic losses, including a 98% decline from 2024 levels, exacerbated by a 10:1 reverse stock split effective August 24, 2026.
The outlook for MSTU is highly risky due to leveraged decay and dependency on MSTR's volatile performance. Investment opportunities are minimal given the fund's history of value destruction, with risks including daily rebalancing losses, crypto market exposure, and lack of fundamental company metrics. Caution is paramount for potential investors.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
